logo
WHO recommends twice-a-year HIV prevention shot as concern looms over funding for global HIV fight

WHO recommends twice-a-year HIV prevention shot as concern looms over funding for global HIV fight

CNN3 days ago
Prescription drugs
WellnessFacebookTweetLink
Follow
The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, lenacapavir, as a tool in their efforts to fight HIV infections – especially for groups most at risk and in areas where the burden of HIV remains high.
The global recommendation – issued Monday at the International AIDS Conference in Kigali, Rwanda – comes about a month after the US Food and Drug Administration approved lenacapavir as a twice-yearly injection for the prevention of the human immunodeficiency virus or HIV. Lenacapavir had been approved in 2022 to treat certain HIV infections and, in trials for prevention, it was found to dramatically reduce the risk of infection and provide almost total protection against HIV.
'These new recommendations are designed for real-world use. WHO is working closely with countries and partners to support the implementation,' Dr. Meg Doherty, director of WHO's Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes, said in a news briefing.
'The first recommendation is that a long-acting injectable, lenacapavir, should be offered as an additional prevention choice for people at risk for HIV and as part of combination prevention. With that, we call it a strong recommendation with moderate to high certainty of the evidence,' Doherty said. The second recommendation in the guidelines is that rapid diagnostic tests like at-home tests can be used to screen someone for HIV when they are starting, continuing or stopping long-acting medication to prevent infection – called pre-exposure prophylaxis, or PrEP.
HIV spreads primarily through unprotected sex or sharing needles. It attacks the body's immune system, and without treatment, it can lead to acquired immunodeficiency syndrome, or AIDS. Globally, about 40 million people were living with HIV at the end of 2023, according to WHO.
PrEP has been used to prevent HIV infections for years. In the United States, this may involve taking pills, such as a daily medication called Truvada, or getting injections, such as every two months of the medication Apretude.
But twice-yearly injections of lenacapavir, or LEN, have become another option in the prevention toolbox – not just for the United States but for the world.
'LEN is a six-monthly injectable option, and it may be particularly attractive for people who prefer fewer clinic visits or have challenges with daily oral PrEP. … It could improve adherence and reach more people who need HIV prevention and can be used in pregnant and breastfeeding women,' Doherty said.
'WHO is providing technical assistance to countries interested in adopting LEN and simplified testing strategies, in coordination with global partners like the Global Fund, UNAIDS and several other partners and donors,' she said. 'We call on governments, funders, implementers and civil society to work together for implementing and integrating LEN into the HIV programs. And we believe time to act is now.'
There has been growing concern around funding for global HIV prevention efforts.
International assistance accounts for 80% of prevention programs in low- and middle-income countries, according to the United Nations. But in the past six months, the United States has significantly withdrawn funding for much of its foreign assistance.
The Trump administration has dismantled the US Agency for International Development, or USAID, and reduced funding for the President's Emergency Plan for AIDS Relief, or PEPFAR, which acts as the largest commitment by any nation to address a single disease in history.
Gilead Sciences, maker of lenacapavir, announced Wednesday that it has reached an agreement with the nonprofit Global Fund to Fight AIDS, Tuberculosis and Malaria to supply lenacapavir for HIV prevention at no profit to the company. Under this agreement, Gilead's pricing reflects only the cost of producing and delivering lenacapavir.
'We are providing the medicine at no profit to Gilead, and in enough supply to reach up to two million people in low- and lower-middle-income countries ahead of generic lenacapavir becoming available,' Gilead Chairman and CEO Daniel O'Day said in a news release.
The company added that the cost of lenacapavir under this agreement remains confidential.
In the United States, the only place where lenacapavir has received approval for HIV prevention so far, the drug has an annual list price of $28,218 when used for HIV prevention. The cost is similar to the price of other prevention medicine options, according to Gilead.
Lenacapavir can 'fundamentally change the trajectory of the HIV epidemic,' but only if it reaches the people who need it most, Peter Sands, executive director of the Global Fund, said in the news release.
'Our ambition is to reach 2 million people with long-acting PrEP. But we can only do that if the world steps up with the resources required,' he said. 'This is a pivotal moment — not just for the fight against HIV, but for the fundamental principle that lifesaving innovations must reach those who need them most — whoever they are, and wherever they live.'
The United Nations warned in a report released Thursday that millions more people could die from HIV-related causes by 2029 if funding for HIV programs permanently disappears.
Among the 60 low- and middle-income countries included in the report, 25 have indicated increasing their domestic budgets for HIV response efforts next year. But the report noted that may not be sufficient to replace the scale of international funding that these countries have been heavily reliant on.
'We know that PEPFAR had committed $4.3 billion to over 50 countries in 2025, and that support was suddenly ended in January of 2025,' Mary Mahy, director of UNAIDS's Data for Impact department, said in a news briefing.
'If none of the PEPFAR funding is replaced, we'd expect something like 4 million additional deaths between 2025 and 2029, and another 6 million additional new infections,' she said. 'We also know that drug resistance would likely occur with some of those people going off treatment.'
Some countries already have seen effects of the rollback of funding for HIV programs, according to Mahy. In Nigeria, facilities reported that there were about 40,000 people who received PrEP at least once during the later part of last year. That number dropped to fewer than 7,000 in April, according to UNAIDS data.
A similar trend emerged in Kenya, where there has been a decline in the number of women living with HIV who recently gave birth and received medications to reduce their risk of transmitting the virus to their newborns. About 3,000 women already received medications and nearly 900 initiated medications in October 2024, but those numbers fell to only about 300 already receiving and 100 starting medications in April.
'This is not just a funding gap — it's a ticking time bomb. … We have seen services vanish overnight. Health workers have been sent home. And people — especially children and key populations — are being pushed out of care,' UNAIDS Executive Director Winnie Byanyima said in a news release Thursday.
'There is still time to transform this crisis into an opportunity,' Byanyima said. 'Countries are stepping up with domestic funding. Communities are showing what works. We now need global solidarity to match their courage and resilience,'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Deodorant sold by Walmart, Amazon recalled nationwide
Deodorant sold by Walmart, Amazon recalled nationwide

The Hill

time10 minutes ago

  • The Hill

Deodorant sold by Walmart, Amazon recalled nationwide

(NewsNation) — Over 67,000 cases of three types of Power Stick deodorant have been recalled due to ' cGMP deviations,' meaning the product did not meet manufacturing regulations by the Food and Drug Administration (FDA). According to an FDA enforcement report, A.P. Deauville initiated the recall on July 10 for 67,214 cases of Power Stick for Her roll-on Antiperspirant Deodorant Powder Fresh, Power Stick Invisible Protection Roll-On Antiperspirant Deodorant Spring Fresh and Power Stick Original Nourishing Invisible Protection Roll-On Antiperspirant Deodorant. The lot numbers of the recalled deodorant, according to the report, are: Power Stick for Her Roll-On: 032026B011, 032226B031, 051626C241, 061526C882, 071226D371, 071226D381, 082526E341 and 082826E402. Power Stick Invisible Protection Roll-On: 031726A991, 041226B561, 062026C901, 062026C911, 071026D351, 071026D361, 071326D391 and 111626G231. Power Stick Original Nourishing Invisible Protection Roll-On: 101225D781, 032926B281, 032826B221, 041126B531, 062226D011, 070626D301, 070626D333, 111026G051, 111326G091 and 111626G221. The antiperspirants were distributed nationwide and sold at Walmart, Amazon and Dollar Tree.

Rep. Garcia of Long Beach asks RFK Jr. to explain targeting of HIV/AIDS funding for cuts
Rep. Garcia of Long Beach asks RFK Jr. to explain targeting of HIV/AIDS funding for cuts

Los Angeles Times

time40 minutes ago

  • Los Angeles Times

Rep. Garcia of Long Beach asks RFK Jr. to explain targeting of HIV/AIDS funding for cuts

Rep. Robert Garcia (D-Long Beach) is calling on Health and Human Services Secretary Robert F. Kennedy Jr. to explain why the Trump administration has repeatedly ordered cuts to HIV/AIDS programs both at home and abroad. In a letter to Kennedy dated Thursday, Garcia asserted that the cabinet secretary has a history of peddling misinformation about the virus and disease, and that the planned cuts — which he called 'alarming and unprecedented' — would cost lives. 'We are concerned that your motivations for disrupting HIV funding and delaying preventative services and research are grounded not in sound science, but in misinformation and disinformation you have spread previously about HIV and AIDS, including your repeated claim that HIV does not cause AIDS,' wrote Garcia, the ranking Democrat on the House Oversight Committee. Health and Human Services officials didn't immediately respond to a request for comment Thursday morning. Kennedy couldn't immediately be reached. Both President Trump and Kennedy have previously defended the sweeping cuts to HHS programs and staff under Kennedy's leadership. Agency spokespeople have said they would allow for a greater focus on Kennedy's priorities of 'ending America's epidemic of chronic illness by focusing on safe, wholesome food, clean water, and the elimination of environmental toxins.' Kennedy has said HHS under his watch 'will do more — a lot more — at a lower cost to the taxpayer.' Garcia's letter — which he co-wrote with Rep. Raja Krishnamoorthi (D-Ill.), the ranking Democrat on the Health Care and Financial Services subcommittee — requested that HHS produce a list of all HIV/AIDS-related funding it has cut and an explanation for how those funds were identified for elimination, as well as other documentation and communications around several of the largest cuts. The letter is the latest attempt by Democrats, in coordination with health experts and LGBTQ+ organizations, to challenge what they see as an inexplicable yet coordinated effort by the Trump administration to dismantle public health initiatives aimed at controlling and ultimately ending one of the most devastating and deadly epidemics in human history. It comes the same day that Senate Republicans agreed to a Trump administration request to claw back billions of dollars in funding for public media and foreign aid, but declined an earlier White House request to include in those cuts about $400 million in HIV/AIDS funding for the President's Emergency Plan for AIDS Relief, or PEPFAR, which is credited with saving millions of lives in some of the poorest nations around the world. The House had previously voted for an earlier version of the measure that did cut the funding for PEPFAR, which was started by President George W. Bush in 2003. However, Senators pushed for the restoration of the funding before agreeing to sign the broader rescission package. The House must now approve the Senate version of the measure by Friday for it to take effect. In an interview with The Times, Garcia said he has long viewed Kennedy as a dangerous 'conspiracy theorist' who has 'peddled in all sorts of lies' about HIV, vaccines and other medical science. Now that Kennedy is HHS secretary, he said, the American people deserve to know whether national and international health decisions are being driven by his baseless personal beliefs. 'Folks need to understand what he's trying to do, and I think that he has to be responsible and be held accountable for his actions,' Garcia said. In their letter, Garcia and Krishnamoorthi noted that recent scientific advancements — including the creation of new preventative drugs — are making the eradication of HIV more attainable than ever. And yet Kennedy and the Trump administration are pushing the nation and the world in the opposite direction, they said. 'Since taking office, the Trump Administration has systematically attacked HIV-related funding and blocked critical HIV-related services and care for those who need it most,' Garcia and Krishnamoorthi wrote. 'These disruptions would threaten Americans most at risk of contracting HIV, and many people living with HIV will get sicker or infect others without programs they rely on for treatment.' The letter outlines a number of examples of such cuts, including: Many in the medical and foreign aid community expressed grave concerns about Kennedy being appointed as HHS secretary, in part because of his past remarks about HIV/AIDS. Kennedy told a reporter for New York Magazine as recently as June 2023 that there 'are much better candidates than H.I.V. for what causes AIDS.' In their letter, Garcia and Krishnamoorthi called out a specific theory shared by Kennedy that the recreational drug known as 'poppers' may cause AIDS, rather than the HIV virus, writing, 'We are deeply concerned that the Trump Administration's HIV-related funding cuts are indiscriminate, rooted in a political agenda, and not at all in the interest of public health.' Kennedy's skepticism about the link between HIV and AIDS conflicts with well established science that has long been accepted by the medical establishment, and by the federal government. Studies around the world have proven the link, and found that HIV is the only common factor in AIDS cases. In August 2023, about a week before Kennedy threw his support behind Trump, his presidential campaign addressed the controversy surrounding his 'poppers' comment, stating that Kennedy did not believe poppers were 'the sole cause' of AIDS, but contended they were 'a significant factor in the disease progression' of early patients in the 1980s. Garcia and Krishnamoorthi also noted a successful effort by local officials and advocates in Los Angeles County to get about $20 million in HIV/AIDS funding restored last month, after it and similar funding nationwide was frozen by the Trump administration. The restoration of those funds followed another letter sent to Kennedy by Rep. Laura Friedman (D-Glendale) and other House members, who cited estimates from the Foundation for AIDS Research, known as amfAR, that the nationwide cuts could lead to 127,000 additional deaths from AIDS-related causes within five years. Garcia and Krishnamoorthi cited the same statistics in their letter. In his interview with The Times, Garcia, who is gay, also said the LGBTQ+ community 'is rightly outraged' at Kennedy's actions to date and deserves to know if Kennedy 'is using his own conspiracy theories and his own warped view of what the facts are' to dismantle public health infrastructure around HIV and AIDS that they fought for decades to build.

More than 67,000 cases of Power Stick deodorant recalled nationwide
More than 67,000 cases of Power Stick deodorant recalled nationwide

Yahoo

timean hour ago

  • Yahoo

More than 67,000 cases of Power Stick deodorant recalled nationwide

More than 67,000 cases of Power Stick deodorants have been recalled for not meeting quality and safety standards. A.P. Deauville, a health and beauty product manufacturer in Pennsylvania, issued a recall for 67,214 cases of Power Stick roll-on deodorant on July 10. The products were recalled for cGMP deviations, which are deviations from established regulations outlined by the Food and Drug Administration (FDA)-enforced Current Good Manufacturing Practices. The recall does not specify a remedy for consumers or which regulations were missed. A.P. Deauville did not immediately respond for comment about the recall when contacted by USA TODAY on Thursday, July 17. What products are listed in the recall? Can't see the table in your browser? Visit Where were the recalled products sold? According to the recall, the Power Stick deodorants were sold nationwide. The deodorants are available for purchase from major retailers such as Walmart and Amazon. What to do with the recalled Power Stick deodorant? The FDA usually recommends discarding recalled products and contacting the manufacturer with any questions you may have. Greta Cross is a national trending reporter at USA TODAY. Story idea? Email her at gcross@ This article originally appeared on USA TODAY: More than 67,000 cases of Power Stick deodorant recalled

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store